private financing Atonarp Raises $50M in Series D Round The Japanese company, which has raised $111 million to date, said the funding will support the development and commercialization of its molecular diagnostic products. Cue Health Raises $235M in Private Funding The company recently received Emergency Use Authorization from the FDA for a SARS-CoV-2 test that runs on its portable molecular diagnostics system. TwinStrand Biosciences Raises $50M in Series B Round The company is commercializing an error-reducing duplex sequencing technology that can identify ultra-low frequency genomic variants. Kromatid Receives $2M Investment From BroadOak Capital Partners The company will use the funds to accelerate commercialization of its directional genomic hybridization products and for ongoing product development. Ultivue Closes $50M Series D Financing Round The company said it would use the funds to expand commercialization of its InSituPlex technology and grow its research and development efforts. Breaking News TruDiagnostic Receives CLIA Certification for Kentucky Laboratory Atonarp Raises $50M in Series D Round Genomtec Gets CE-IVD Mark for Saliva-Based Molecular SARS-CoV-2 Test Oncocyte Posts $1.1M in Q1 Revenues, Beating Wall Street Expectations Namocell, SingLab Technologies Ink Distribution Agreement for Singapore Mitochondrial DNA Analysis Uncovers Influence of Genetic Variation on Hundreds of Phenotypes The Scan Gap in COVAX Doses BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports. Sanofi, GSK Report Promising Results The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results. Influence of Luck The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases. PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.